Therapeutic innovations in endocrine diseases – Part 1: New medical treatments for chronic excess of endogenous cortisol (Cushing's syndrome)

SummaryDiverse hormonal, antisecretory, antitumoural or immunomodulatory therapeutic innovations act for broadening the management scope of adrenal, pituitary and endocrine tumours.In this issueInnovations in autoimmune diseasesL. Guillevin, FranceStem cell transplantation and mesenchymal cells to treat autoimmune diseasesA. Tyndall, Switzerland, and J.M. van Laar, NetherlandsNew therapeutic approaches for ANCA-associated vasculitidesB. Chaigne, L. Guillevin, FranceNew therapeutic approaches in rheumatoid arthritisR.F. van Vollenhoven, SwedenFuture treatments for Sjögren's syndromeJ.-O. Pers, A. Saraux, FranceTherapeutic innovations in endocrine diseases: part 1: new medical treatments for chronic excess of endogenous cortisol (Cushing's syndrome)X. Bertagna, FranceTherapeutic innovations in endocrine diseases: part 2: modified-release glucocorticoid compounds: what good do they provide to the adrenal insufficient patient?Y. Reznik, FranceTherapeutic innovations in endocrine diseases: part 3: temozolomide and future therapeutics for aggressive pituitary tumors and carcinomasH. Lasolle, G. Raverot, FranceTherapeutic innovations in endocrine diseases: part 4: pasireotide: long-acting release somatostatin analogueJ.-L. Wémeau, FranceTherapeutic innovations in endocrine diseases: part 5: rituximab and graves’ orbitopathyM. Ladsous, France